August 28, 2014 Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile
August 26, 2014 Synthetic Biologics Announces Presentation of Poster for SYN-004 C. difficile Program at IDWeek 2014™
August 19, 2014 Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
August 14, 2014 Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
August 12, 2014 Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
August 5, 2014 Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
July 31, 2014 Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta™ in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting
July 29, 2014 Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
